US2680755A - Method of obtaining trans polyene compounds - Google Patents
Method of obtaining trans polyene compounds Download PDFInfo
- Publication number
- US2680755A US2680755A US267687A US26768752A US2680755A US 2680755 A US2680755 A US 2680755A US 267687 A US267687 A US 267687A US 26768752 A US26768752 A US 26768752A US 2680755 A US2680755 A US 2680755A
- Authority
- US
- United States
- Prior art keywords
- trans
- unsaturated
- acid
- vitamin
- isomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
- C07C403/06—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms
- C07C403/08—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms by hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
- C07C403/06—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms
- C07C403/12—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms by esterified hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
- C07C403/20—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by carboxyl groups or halides, anhydrides, or (thio)esters thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/09—Geometrical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Definitions
- fi-ionylidene acetic acid which forms a valuable intermediate in vitamin A syntheses, should have the structure and such acid as well as the correspondin esters should also have a trans configuration with respect to the second olefinic double bond from the rin to facilitate the production of vitamin A material having a high level or biological activity.
- vitamin A acid and 6-ionylidene acetic acid or esters of such acids are obtained in the desired ocfi-llllsaturated form, however, they often exist as a mixture of cis and trans isomers with respect to the second olefinic double bond from the ring.
- Another object of the invention is to provide an improved method of obtaining vitamin A acid in the form exhibiting a high level of biological activity.
- Another object of the invention is to facilitate the use of Reformatsky or similar reactions causing isomerization in the synthesis of vitamin A by providing means for obviating the 0bjectionable effects normally attendant to the use of such reactions.
- Another object of the invention is to provide a simple but effective method for concomitantly converting cis vac-unsaturated polyene acids or esters of the vitamin A series to the corresponding trans il-unsaturated acids or esters and for recovering the trans cap-unsaturated acids or esters in crystalline form.
- Another object of the invention is to reduce 3 the content of relatively inactive material in the products obtained by conventional vitamin A syntheses which yield vitamin A acid during the synthesis.
- Another object of the invention is to increase the available supply of highly potent vitamin A by converting other less desirable isomers to more active form.
- the [a -unsaturated isomers of the desired a,;3-unsaturated polyene acids and esters are readily converted to the desired cap-unsaturated form, usually as a mixture of the cis and trans forms, and the trans form is progressively crystallized out of the solution while the cis form is concomitantly converted to the trans form.
- the polyene acid, B-ionylidene acetic acid is readily formed in accordance with known practice by subjecting B-ionone to a Reformatsky reaction with ethyl bromoacetate, followed by v dehydration of the resulting B-ionolacetic acid ester and saponification to form the acid according to the following equations, the ester being an intermediate in such process:
- vitamin A acid is commonly obtained as a mixture of the cis and trans forms of the a,;3-unsaturated vitamin A acid, and in many cases, in an admixture of the cis and trans forms of a e-unsaturated vitamin A acid having the formula and the iq-unsaturated desmotropic isomer of vitamin A acid having the formula H CH3 CH3 CH2 It is therefore necessary to convert both the n-unsaturated isomer and the cis form of the c p-unsaturated vitamin A acid to the desired trans vitamin A acid to obtain a good yield of highly potent vitamin A acid.
- any of the well-known hydrogen halides and preferably either hydrogen chloride or hydrogen bromide, either in anhydrous form or as an aqueous acid, is used for effecting conversion to the desired trans l p-unsaturated polyene compound in a solution in either acetonitrile or nitromethane, and the trans i c-unsaturated polyene compound crystallizes out of such a solution in substantially pure form at room temperature.
- the process is applicable for obtaining [i-ionylidene acetic acid or vitamin A acid, or any of the well-known esters of such acids including alkyl, aryl and arallryl esters, with the alkyl esters such as methyl, ethyl, propyl or similar alkyl esters being preferred for convenience.
- alkyl esters such as methyl, ethyl, propyl or similar alkyl esters being preferred for convenience.
- Compound I Compound 11 sary.
- the process is desirably carried out in a reaction mixture wherein the acid concentration of the hydrogen halide is from 0.1 N to 1.0 N. Lower concentrations can be used but the process proceeds rather slowly, and concentrations substantially above 1 N lead to some destruction of the polyene compounds.
- Example 1 A two hundred grain portion of the ethyl ester of fl-ionylidene acetic acid, obtained by a Reformatsky reaction between c-ionone and ethyl bromoacetate followed by dehydration with phosphorous oxychloride in pyridine in accordance with usual practice and having was dissolved in 1000 cc. of ethanol. A solution of 350 g. of potassium hydroxide in 1500 cc. of water was added to the ethanol solution and the resulting mixture was heated at 70-80 C. for 45 minutes. The mixture was then cooled, diluted with 5000 cc.
- Example 2 A 1.8 g. portion of mixed (ac-unsaturated and d -unsaturated c-ionylidene acetic acids of 85%
- Example 4 The invention is equally applicable for obtaining trans pt-unsaturated polyene esters.
- 3.0 g. of the ,cyy-unsaturated isomer of [3ionylidene acetic acid having Eiem. (284 m :1140 was dissolved in 15 cc. of water, made slightly alkaline with 10% aqueous sodium hydroxide, mixed with 30 cc. of ethanol and 3.6 g. of p-phenylphenacyl bromide and the resulting mixture refluxed for one hour.
- esters such as the phenyl, benzyl, p-nitrobenzyl, phenacyl and similar esters as well as with the conveniently employed allzyl esters.
- trans a,,B- unsaturated fi-ionylidene acetic acid and trans gr-unsaturated vitamin A acid and esters of such acids are readily obtained in crystalline form, and the undesirable cis isomers and ;8,y-unsaturated desmotropic isomers of such acids and esters are converted to the desired trans form in good yield and by a single reaction step.
- n is an integer of the series consisting of 1 and 2 and esters of such acids, which method comprises treating a mixture of said trans 01,5- unsaturated polyene compound and the corresponding cis isomer of said compound in solution in acetonitrile with a hydrogen halide, and selectively crystallizing said trans lip-unsaturated compound from said solution in an amount greater than the amount or" said trans d e-unsaturated compound originally present in said mixture and substantially free of said cis isomer.
- the method of obtaining crystalline fi-ionylidene acetic acid having a trans configuration with respect to the second olefinic double bond from the ring comprises treating with a hydrogen halide a mixture of trans p-ionylidene acetic acid in solution in a solvent selected from the class consisting of acetonitrile and nitromethane, and progressively and selectively crystallizing trans e-ionylidene acetic acid from said solution in crystalline form and substantially free of said cis isomer.
- the method of obtaining crystalline vitamin A acid having a trans configuration with respect to thesecond olefinic double bond from the ring comprises treating with a hydrogen halide a solution of a mixture of trans vitamin A acid and cis vitamin A acid in a solvent selected from the class consisting of acetonitrile and nitromethane, and progressively and selectively crystallizing trans vitamin A acid from said solution in crystalline form and substantially free of said cis isomer.
- the method of obtaining in good yield the crystalline trans isomeric form of an B-unsaturated polyene compound selected from the group consisting of polyene acids or the formula H18 CH2 wherein n is an integer of the series consistin of 1 and 2, and esters of said acids which method comprises dissolving a fi -unsaturated isomer of said (lip-unsaturated polyene compound in a solvent selected .from the class consisting of acetonitrile and nitrornethane, treating said 5, unsaturated isomer in said solution with a hydrogen halide and thereby converting said fiyy-Lll'lsaturated isomer to a mixture of the cis and trans forms of said a, 3-unsaturated polyene compound, and selectively crystallizing the trans form of said a, B-llIlS3.l)l1l'tt1 polyene compound from said solution concomitant with said converting and substantially free of said cis isomer, said
- the method of obtaining in good yield ionylidene acetic acid in the iorm'having a trans configuration with respect to the second oleflnic double bond from the ring comprises dissolving a ⁇ iv-unsaturated isomer of eionylidene acetic acid having the formula in a solvent selected from the class consisting of acetonitrile and nitromethane, treating saidd'yunsaturated isomer in the resulting solution with a hydrogen halide and thereby converting said [aw-unsaturated isomer to a mixture of cis and trans fi-ionylidene acetic acid and concomitantly selectively crystallizing trans peionylidene acetic acid from said solution in crystalline form and substantially free of said cis l3-ionylidene acetic acid.
- the method of obtaining in good yield vitamin A acid'in the form characterized by atrans configuration with respect to the second olefinic double bond from the ring comprises dissolving a c,'y-unsaturated isomer of vitamin A acid having'the formula HsC 6E1 CH3 CH3 in a solvent selected from the class consisting of acetonitrile and nitromethane, treating said pry-unsaturated isomer in the resulting solution with a hydrogen halide and thereby convertand, while said firy-unsaturated isomer is in solution in said acetonitrile, treating said ,8,'y-unsaturated isomer with hydrogen chloride and thereby converting said flxv-unsaturated isomer to a mixture of cis and trans ,B-ionylidene acetic acid and selectively crystallizing trans ,e-ionylidene acetic acid from said solution concomitant With said converting and. substantially free
- the method of obtaining in good yield vitamin A acid in the form having a trans configuration With respect to the second olefinic double bond from the ring comprises dissolving in acetonitrile a fi/Y-unsaturated isomer of vitamin A acid having the formula 113C CH3 treating said dry-unsaturated isomer in the resulting solution with hydrogen chloride and thereby concomitantly converting said [i -unsaturated isomer to a mixture of cis and trans vitamin A acid and selectively crystallizing trans vitamin A acid from said solution in crystalline form substantially free of said cis vitamin A acid, said cis vitamin A acid being converted to trans vitamin A acid during said crystallizing.
Description
Patented June 8, 195 4 UNITED STATES PATENT OFFICE METHQD F OBTAINING TRANS POLYENE I COMPOUNDS Charles 'D. Robeson and James G. Baxter, Rochester, N. Y., assignors to Eastman Kodak Company, Rochester, N. Y., a corporation of New Jersey No Drawing. Application January 22, 1952, Serial No. 267,687
11 Claims. (01. 260-413) and should also have a trans configuration with respect to the second olefinic double bond from the ring for maximum vitamin A activity as measured by standard bioassay methods. Other vitamin A-active materials, such as vitamin A esters, similarly require a trans configuration for optimum activity.
similarly, fi-ionylidene acetic acid, which forms a valuable intermediate in vitamin A syntheses, should have the structure and such acid as well as the correspondin esters should also have a trans configuration with respect to the second olefinic double bond from the rin to facilitate the production of vitamin A material having a high level or biological activity.
In the synthesis of vitamin A acid and the intermediate s-ionylidene acetic acid or the esters of such acids, the inherent instability of these materials often gives rise to the formation of mixtures of the desired mfl-UIISELtllIfitGd and completely conjugated compounds and desmotropic li -unsaturated isomers of the desired polyene compounds. Thus, for example, in the manu facture of fi-ionylidene acetic acid, the use of a Reformatsky reaction and dehydration of the resultant hydroxy compound results in the formation of a [iv-unsaturated isomer of B-ionylidene acetic acid probably having the formula CHa in admixture with the desired B-unsaturated B-ionylidene acetic acid; and similarly the use of a Reformatsky reaction and dehydration in the preparation of vitamin A acid results in the formation of sp -unsaturated isomer of vitamin A acid probably having the formula I V'GHB in admixture with the desired orb-unsatu ate vitamin A acid. For optimumyield, it is necessary to convert such iv-unsaturated isomers to the desired il-unsaturated form.
Even when vitamin A acid and 6-ionylidene acetic acid or esters of such acids, such as the alkyl esters, are obtained in the desired ocfi-llllsaturated form, however, they often exist as a mixture of cis and trans isomers with respect to the second olefinic double bond from the ring. For optimum yield of the desired lip-unsaturated trans form in relatively pure form, it therefore becomes necessary to separate the trans isomer from the cis isomer and to convert the cis isomer to the trans isomer.
It is accordingly an object of this invention to provide an improved process for obtaining in good yield ,B-UIISfltllTfitBd polyene acids and esters in the trans form with respect to the olefinic unsaturation.
It is another object of the invention to provide an effective method for converting {iv-unsaturated isomers of p-ionylidene acetic acid or vitamin A acid or esters thereof to the correspondin trans ri e-unsaturated acid or ester and for recovering such trans a s-unsaturated acid or ester in crystalline form and substantially free of cis il-unsaturated acid or ester.
Another object of the invention is to provide an improved method of obtaining vitamin A acid in the form exhibiting a high level of biological activity.
Another object of the invention is to facilitate the use of Reformatsky or similar reactions causing isomerization in the synthesis of vitamin A by providing means for obviating the 0bjectionable effects normally attendant to the use of such reactions.
Another object of the invention is to provide a simple but effective method for concomitantly converting cis vac-unsaturated polyene acids or esters of the vitamin A series to the corresponding trans il-unsaturated acids or esters and for recovering the trans cap-unsaturated acids or esters in crystalline form.
Another object of the invention is to reduce 3 the content of relatively inactive material in the products obtained by conventional vitamin A syntheses which yield vitamin A acid during the synthesis.
Another object of the invention is to increase the available supply of highly potent vitamin A by converting other less desirable isomers to more active form.
Other objects will be apparent from the description and claims which follow.
These and other objects are successfully attained by means of this invention as described more fully hereinafter. We have discovered that crystalline sip-unsaturated polyene acids or esters thereof, having a trans configuration with respect to the second olefinic double bond from the ring and having the formula H39 CH;
treated in accordance with the invention, since the mixture is usually obtained in vitamin A syntheses and not the pure cis form.
We have discovered further that by the processes embodying this invention, the [a -unsaturated isomers of the desired a,;3-unsaturated polyene acids and esters are readily converted to the desired cap-unsaturated form, usually as a mixture of the cis and trans forms, and the trans form is progressively crystallized out of the solution while the cis form is concomitantly converted to the trans form.
The polyene acid, B-ionylidene acetic acid, is readily formed in accordance with known practice by subjecting B-ionone to a Reformatsky reaction with ethyl bromoacetate, followed by v dehydration of the resulting B-ionolacetic acid ester and saponification to form the acid according to the following equations, the ester being an intermediate in such process:
i CH=CHO=O Zn ercnioooozrn F is present in an amount of not more than about of the total product and usually less than this amount, and it becomes necessary to separate the desired trans isomer in order to continue the synthesis to vitamin A and obtain a highly active material and to convert a substantial portion of the material other than trans a s-unsaturated ,B-ionylidene acetic acid to this desired form.
Similarly, vitamin A acid is commonly obtained as a mixture of the cis and trans forms of the a,;3-unsaturated vitamin A acid, and in many cases, in an admixture of the cis and trans forms of a e-unsaturated vitamin A acid having the formula and the iq-unsaturated desmotropic isomer of vitamin A acid having the formula H CH3 CH3 CH2 It is therefore necessary to convert both the n-unsaturated isomer and the cis form of the c p-unsaturated vitamin A acid to the desired trans vitamin A acid to obtain a good yield of highly potent vitamin A acid.
In the process embodying this invention, any of the well-known hydrogen halides, and preferably either hydrogen chloride or hydrogen bromide, either in anhydrous form or as an aqueous acid, is used for effecting conversion to the desired trans l p-unsaturated polyene compound in a solution in either acetonitrile or nitromethane, and the trans i c-unsaturated polyene compound crystallizes out of such a solution in substantially pure form at room temperature. The process is applicable for obtaining [i-ionylidene acetic acid or vitamin A acid, or any of the well-known esters of such acids including alkyl, aryl and arallryl esters, with the alkyl esters such as methyl, ethyl, propyl or similar alkyl esters being preferred for convenience. By means of this invention, a substantial proportion of the cis il-unsaturated polyene compound is converted to the desired trans form concomitant withthe crystallization and is progressively crys- Dehydration B50 CH CH3 CE;
Compound I Compound 11 sary. The process is desirably carried out in a reaction mixture wherein the acid concentration of the hydrogen halide is from 0.1 N to 1.0 N. Lower concentrations can be used but the process proceeds rather slowly, and concentrations substantially above 1 N lead to some destruction of the polyene compounds.
The invention is illustrated by the following examples with regard to certain preferred embodiments of the invention.
Example 1 A two hundred grain portion of the ethyl ester of fl-ionylidene acetic acid, obtained by a Reformatsky reaction between c-ionone and ethyl bromoacetate followed by dehydration with phosphorous oxychloride in pyridine in accordance with usual practice and having was dissolved in 1000 cc. of ethanol. A solution of 350 g. of potassium hydroxide in 1500 cc. of water was added to the ethanol solution and the resulting mixture was heated at 70-80 C. for 45 minutes. The mixture was then cooled, diluted with 5000 cc. of water, extracted with ether, the soap layer acidified with 10% aqueous sulfuric acid, and the mixed fi-ionylidene acetic acids extracted out with ether. The ether extract was washed with a 10% aqueous solution of sodium sulfate, dried over anhydrous sodium sulfate, and the ether removed by evaporation to give 161.5 g. or" mixed B-ionylidene acetic acids having E1em. (283 m )=795 and consisting of approximately equal amounts of Dip-unsaturated c-ionylidene acetic acid and the {R -unsaturated desrnotropic isomer of such acid with somewhat less than half of the a s-unsaturated portion being present in the desired trans form.
A 79 g. portion of such mixed acids was dissolved in 80 cc. of acetronitrile with no hydrogen halide present and the resulting solution was allowed to stand at room temperature for several hours. The crystallized trans a,5-u1isatu1ated ,B-ionylidene acetic acid was filtered out and amounted to 12 g. of acid having a melting point of 124-125 C. and E1cm. (297 m )=630, which corresponded to a yield of only 15.2% of the desired trans form.
A similar 79 g. portion of the mixed ,B-ionylidene acetic acid was dissolved in 80 cc. of acetonitrile containing 0.29 g. of anhydrous hydrogen chloride and the resulting solution was allowed to stand at room temperature for several hours as before. Filtration of the crystallized product yielded 48.2 g. of the desired trans a e-unsaturated c-ionylidene acetic acid having a melting point of 124-l25 C. and having E1cm. (297 m :632 or a yield of 61% of the desired trans acid.
Example 2 A 1.8 g. portion of mixed (ac-unsaturated and d -unsaturated c-ionylidene acetic acids of 85% Example 3 A 100 g. portion of a concentrate of vitamin A acid in admixture with its [R -unsaturated isomer was dissolved in 280 ml. of acetonitrile containing 20 ml. of 1.6 N hydrochloric acid in methanol. Crystals began to precipitate in a few minutes and the solution was filtered after standing for 2 hours. The crystallized trans vitamin A acid obtained upon filtering weighed 35 g. and had E1cm. (352 m i)=l366 and a melting point of 166-167 C. The trans vitamin A acid obtained thereby was then reduced to vitamin A alcohol and esterified to vitamin A acetate in accordance with conventional techniques and assayed at 2,420,000 vitamin A units per gram.
Example 4 The invention is equally applicable for obtaining trans pt-unsaturated polyene esters. Thus, 3.0 g. of the ,cyy-unsaturated isomer of [3ionylidene acetic acid having Eiem. (284 m :1140 was dissolved in 15 cc. of water, made slightly alkaline with 10% aqueous sodium hydroxide, mixed with 30 cc. of ethanol and 3.6 g. of p-phenylphenacyl bromide and the resulting mixture refluxed for one hour. The cr -unsaturated p-phenylphenacyl ester of ,c-ionylidene acetic acid obtained thereby was a brown oil weighing 4.48 g. and having E1cm. 284 m :977. A 1.5 g. portion of this ester was dissolved in 3 cc. of nitromethane containing 53.5 mg. of hydrochlo ric acid. The resulting mixture was allowed to stand at room temperature for 17 hours and 0.66 g. of trans raw-unsaturated ester was obtained having Emn. (285 n1;;.)=03 in cyclohexane.
Similar results are obtained with other esters such as the phenyl, benzyl, p-nitrobenzyl, phenacyl and similar esters as well as with the conveniently employed allzyl esters.
Thus, by means of this invention, trans a,,B- unsaturated fi-ionylidene acetic acid and trans gr-unsaturated vitamin A acid and esters of such acids are readily obtained in crystalline form, and the undesirable cis isomers and ;8,y-unsaturated desmotropic isomers of such acids and esters are converted to the desired trans form in good yield and by a single reaction step.
While the invention has been described in considerable detail with reference to certain preferred embodiments thereof, it will be understood that variations and modifications can be efiected within the spirit and scope of the invention as described hereinabove and as defined in the appended claims.
We claim:
1. The method of obtaining a crystalline ,6- unsaturated polyene compound having a trans configuration with respect to the second olefinic double bond from the ring and having the formula wherein R is selected from the group consisting of hydrogen and hydrocarbon radicals and n is an integer of the series consisting of l and 2, which method comprises treating a cis isomer of said compound with a hydrogen halide in solu tion in a solvent selected from the class consisting of acetonitrile and nitromethane, and selectively crystallizing the trans a d-unsaturated polyene compound out of said solution in crystalline form and substantially free of said cis isomer.
2. The method of obtaining a crystalline 0a,,8- unsaturated polyene compound having a trans p-ionylidene acetic acid and cis configuration with respect to the second olefinic double bond fromthe ring and having the formula wherein R. is selected from the group consisting .of hydrogen and hydrocarbon radicals and n is an integer of the series consisting of l and 2, which method comprises treating a mixture of said trans r p-unsaturated olyene compound and the corresponding cis isomer of said compound with a hydrogen halide in solution in a solvent selected from the class consisting of acetonitrile and nitromethane, and progressively and selecthe formula Has CH3 r lcn=on-e=cn -ooon I on,
wherein n is an integer of the series consisting of 1 and 2 and esters of such acids, which method comprises treating a mixture of said trans 01,5- unsaturated polyene compound and the corresponding cis isomer of said compound in solution in acetonitrile with a hydrogen halide, and selectively crystallizing said trans lip-unsaturated compound from said solution in an amount greater than the amount or" said trans d e-unsaturated compound originally present in said mixture and substantially free of said cis isomer.
4. The method of obtaining a crystalline 01$- unsaturated polyene compound having a trans configuration with respect to the second olefinic double bond from the ring and being selected from the group consisting of polyene acids having the formula HaC CH3 wherein n is an integer of the series consisting of l and 2, and esters of such acids, which method comprises treating a mixture of said trans 04,5- unsaturated polyene compound and the corresponding cis isomer of said compound, in solution in a solvent selected from the class consisting of acetonitrile and nitromethane, with hydro gen chloride, and selectively crystallizing from said solution said trans a,{3-unsaturated polyene compound substantially free of said cis isomer.
5. The method of obtaining crystalline fi-ionylidene acetic acid having a trans configuration with respect to the second olefinic double bond from the ring, which method comprises treating with a hydrogen halide a mixture of trans p-ionylidene acetic acid in solution in a solvent selected from the class consisting of acetonitrile and nitromethane, and progressively and selectively crystallizing trans e-ionylidene acetic acid from said solution in crystalline form and substantially free of said cis isomer.
6. The method of obtaining crystalline vitamin A acid having a trans configuration with respect to thesecond olefinic double bond from the ring, which method comprises treating with a hydrogen halide a solution of a mixture of trans vitamin A acid and cis vitamin A acid in a solvent selected from the class consisting of acetonitrile and nitromethane, and progressively and selectively crystallizing trans vitamin A acid from said solution in crystalline form and substantially free of said cis isomer.
'7. The method of obtaining in good yield the crystalline trans isomeric form of an B-unsaturated polyene compound selected from the group consisting of polyene acids or the formula H18 CH2 wherein n is an integer of the series consistin of 1 and 2, and esters of said acids, which method comprises dissolving a fi -unsaturated isomer of said (lip-unsaturated polyene compound in a solvent selected .from the class consisting of acetonitrile and nitrornethane, treating said 5, unsaturated isomer in said solution with a hydrogen halide and thereby converting said fiyy-Lll'lsaturated isomer to a mixture of the cis and trans forms of said a, 3-unsaturated polyene compound, and selectively crystallizing the trans form of said a, B-llIlS3.l)l1l'tt1 polyene compound from said solution concomitant with said converting and substantially free of said cis isomer, said cis form being at least partially converted to said trans form during said crystallizing.
8. The method of obtaining in good yield ionylidene acetic acid in the iorm'having a trans configuration with respect to the second oleflnic double bond from the ring, which method comprises dissolving a {iv-unsaturated isomer of eionylidene acetic acid having the formula in a solvent selected from the class consisting of acetonitrile and nitromethane, treating saidd'yunsaturated isomer in the resulting solution with a hydrogen halide and thereby converting said [aw-unsaturated isomer to a mixture of cis and trans fi-ionylidene acetic acid and concomitantly selectively crystallizing trans peionylidene acetic acid from said solution in crystalline form and substantially free of said cis l3-ionylidene acetic acid.
9. The method of obtaining in good yield vitamin A acid'in the form characterized by atrans configuration with respect to the second olefinic double bond from the ring, which method comprises dissolving a c,'y-unsaturated isomer of vitamin A acid having'the formula HsC 6E1 CH3 CH3 in a solvent selected from the class consisting of acetonitrile and nitromethane, treating said pry-unsaturated isomer in the resulting solution with a hydrogen halide and thereby convertand, while said firy-unsaturated isomer is in solution in said acetonitrile, treating said ,8,'y-unsaturated isomer with hydrogen chloride and thereby converting said flxv-unsaturated isomer to a mixture of cis and trans ,B-ionylidene acetic acid and selectively crystallizing trans ,e-ionylidene acetic acid from said solution concomitant With said converting and. substantially free of said cis ,3-ionylidene acetic acid, said cis B-ionylidene acetic acid being converted to trans fl-ionylidene acetic acid during said crystallizing.
11. The method of obtaining in good yield vitamin A acid in the form having a trans configuration With respect to the second olefinic double bond from the ring, which method comprises dissolving in acetonitrile a fi/Y-unsaturated isomer of vitamin A acid having the formula 113C CH3 treating said dry-unsaturated isomer in the resulting solution with hydrogen chloride and thereby concomitantly converting said [i -unsaturated isomer to a mixture of cis and trans vitamin A acid and selectively crystallizing trans vitamin A acid from said solution in crystalline form substantially free of said cis vitamin A acid, said cis vitamin A acid being converted to trans vitamin A acid during said crystallizing.
References Cited in the file of this patent UNITED STATES PATENTS Number Name Date 2,576,103 Shantz et al Nov. 27, 1951 2,576,104 Cawley et a1 Nov. 27, 1951 OTHER REFERENCES Newman et al., Chem. Abstracts, vol. 41, col. 2403 (1947).
Gilman, Organic Chem, vol. 1, p. 376 (1938). (Copies in Sci. Library.)
Claims (1)
1. THE METHOD OF OBTAINING A CRYSTALLINE A,BUNSATURATED POLYENE COMPOUND HAVING A TRANS CONFIGURATION WITH RESPECT TO THE SECOND OLEFINIC DOUBLE BOND FROM THE RING AND HAVING THE FORMULA
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US267687A US2680755A (en) | 1952-01-22 | 1952-01-22 | Method of obtaining trans polyene compounds |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US267687A US2680755A (en) | 1952-01-22 | 1952-01-22 | Method of obtaining trans polyene compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US2680755A true US2680755A (en) | 1954-06-08 |
Family
ID=23019774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US267687A Expired - Lifetime US2680755A (en) | 1952-01-22 | 1952-01-22 | Method of obtaining trans polyene compounds |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | US2680755A (en) |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2870197A (en) * | 1954-12-24 | 1959-01-20 | Hoffmann La Roche | 4, 4'-disubstituted-c40-carotenoids and their preparation |
| US3056834A (en) * | 1953-01-22 | 1962-10-02 | Philips Corp | Synthesis of vitamin a |
| US3069460A (en) * | 1958-12-19 | 1962-12-18 | Bayer Ag | Process for the production of alpha, beta-unsaturated acids of the vitamin a series |
| US3143564A (en) * | 1962-01-15 | 1964-08-04 | Sumitomo Chemical Co | Method for producing 2-transvitamin a acid |
| US4044051A (en) * | 1971-12-22 | 1977-08-23 | Hoffmann-La Roche Inc. | 9[2-(1-Alkoxy-ethyl)-5,5-dimethyl-cyclopent-1-en-1-yl]-3,7-dimethyl-nona-2,4,6,8-tetraen acid compounds |
| US6495719B2 (en) | 2001-03-27 | 2002-12-17 | Circagen Pharmaceutical | Histone deacetylase inhibitors |
| US20030125306A1 (en) * | 2001-03-27 | 2003-07-03 | Circagen Pharmaceutical, A Delaware Corporation | Histone deacetylase inhibitors |
| US20040167184A1 (en) * | 2001-03-27 | 2004-08-26 | Wiech Norbert L. | Treatment of lung cells with histone deacetylase inhibitors |
| US20060160902A1 (en) * | 2004-11-08 | 2006-07-20 | Wiech Norbert L | Histone deacetylase inhibitors |
| US20070037869A1 (en) * | 2001-03-27 | 2007-02-15 | Hsuan-Yin Lan-Hargest | Histone deacetylase inhibitors |
| US20100143961A1 (en) * | 2002-05-22 | 2010-06-10 | Hsuan-Lin Lan-Hargest | Histone deacetylase inhibitors based on alpha-ketoepoxide compounds |
| US8026280B2 (en) | 2001-03-27 | 2011-09-27 | Errant Gene Therapeutics, Llc | Histone deacetylase inhibitors |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2576103A (en) * | 1946-12-24 | 1951-11-27 | Eastman Kodak Co | Synthesis of vitamin a active compounds containing repeated isoprene units |
| US2576104A (en) * | 1946-12-24 | 1951-11-27 | Eastman Kodak Co | Dehydration and isomerization of straight-chain-conjugated polyene esters and acids |
-
1952
- 1952-01-22 US US267687A patent/US2680755A/en not_active Expired - Lifetime
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2576103A (en) * | 1946-12-24 | 1951-11-27 | Eastman Kodak Co | Synthesis of vitamin a active compounds containing repeated isoprene units |
| US2576104A (en) * | 1946-12-24 | 1951-11-27 | Eastman Kodak Co | Dehydration and isomerization of straight-chain-conjugated polyene esters and acids |
Cited By (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3056834A (en) * | 1953-01-22 | 1962-10-02 | Philips Corp | Synthesis of vitamin a |
| US2870197A (en) * | 1954-12-24 | 1959-01-20 | Hoffmann La Roche | 4, 4'-disubstituted-c40-carotenoids and their preparation |
| US3069460A (en) * | 1958-12-19 | 1962-12-18 | Bayer Ag | Process for the production of alpha, beta-unsaturated acids of the vitamin a series |
| US3143564A (en) * | 1962-01-15 | 1964-08-04 | Sumitomo Chemical Co | Method for producing 2-transvitamin a acid |
| US4044051A (en) * | 1971-12-22 | 1977-08-23 | Hoffmann-La Roche Inc. | 9[2-(1-Alkoxy-ethyl)-5,5-dimethyl-cyclopent-1-en-1-yl]-3,7-dimethyl-nona-2,4,6,8-tetraen acid compounds |
| US20070037869A1 (en) * | 2001-03-27 | 2007-02-15 | Hsuan-Yin Lan-Hargest | Histone deacetylase inhibitors |
| US8026280B2 (en) | 2001-03-27 | 2011-09-27 | Errant Gene Therapeutics, Llc | Histone deacetylase inhibitors |
| US20030125306A1 (en) * | 2001-03-27 | 2003-07-03 | Circagen Pharmaceutical, A Delaware Corporation | Histone deacetylase inhibitors |
| US20040167184A1 (en) * | 2001-03-27 | 2004-08-26 | Wiech Norbert L. | Treatment of lung cells with histone deacetylase inhibitors |
| US9486421B2 (en) | 2001-03-27 | 2016-11-08 | Errant Gene Therapeutics, Llc | Treatment of lung cells with histone deacetylase inhibitors |
| US6495719B2 (en) | 2001-03-27 | 2002-12-17 | Circagen Pharmaceutical | Histone deacetylase inhibitors |
| US7312247B2 (en) | 2001-03-27 | 2007-12-25 | Errant Gene Therapeutics, Llc | Histone deacetylase inhibitors |
| US7314953B2 (en) | 2001-03-27 | 2008-01-01 | Errant Gene Therapeutics, Llc | Treatment of lung cells with histone deacetylase inhibitors |
| US20080312324A1 (en) * | 2001-03-27 | 2008-12-18 | Hsuan-Yin Lan-Hargest | Treatment of lung cells with histone deacetylase inhibitors |
| US8420698B2 (en) | 2001-03-27 | 2013-04-16 | Errant Gene Therapeutics, Llc | Histone deacetylase inhibitors |
| US7842727B2 (en) | 2001-03-27 | 2010-11-30 | Errant Gene Therapeutics, Llc | Histone deacetylase inhibitors |
| US7858664B2 (en) | 2001-03-27 | 2010-12-28 | Errant Gene Therapeutics, Llc | Histone deacetylase inhibitors |
| US7902259B2 (en) | 2001-03-27 | 2011-03-08 | Errant Gene Therapeutics, Llc | Histone deacetylase inhibitors |
| US20030083521A1 (en) * | 2001-03-27 | 2003-05-01 | Circagen Pharmaceutical, A Maryland Corporation | Histone deacetylase inhibitors |
| US8138225B2 (en) | 2002-05-22 | 2012-03-20 | Errant Gene Therapeutics, Llc | Histone deacetylase inhibitors based on alpha-ketoepoxide compounds |
| US20100143961A1 (en) * | 2002-05-22 | 2010-06-10 | Hsuan-Lin Lan-Hargest | Histone deacetylase inhibitors based on alpha-ketoepoxide compounds |
| US20060160902A1 (en) * | 2004-11-08 | 2006-07-20 | Wiech Norbert L | Histone deacetylase inhibitors |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US2680755A (en) | Method of obtaining trans polyene compounds | |
| Barthel et al. | Preparation of the chrysanthemumates of 6-bromo-and 6-chloropiperonyl alcohols | |
| US3532721A (en) | Cyclopentyl-alkanoic acids | |
| US2576104A (en) | Dehydration and isomerization of straight-chain-conjugated polyene esters and acids | |
| US3896156A (en) | Dihydroprostaglandin e, analogs | |
| US3989758A (en) | Monoacetals of unsaturated aliphatic dialdehydes | |
| US3102127A (en) | 19-methylene-androstane derivatives | |
| US3159649A (en) | 2-oxy-5-(6-oxy-2-naphthyl) cyclopentanealkanoic acids, their esters, and corresponding lactones | |
| US2709712A (en) | Synthesis of vitamin a-active polyenes | |
| US2583594A (en) | Esterification of polyene acids | |
| US2880233A (en) | Compounds of the perhydrochrysene and related series and preparation thereof | |
| EP0111325B1 (en) | Process for the preparation of 13-cis-retinoic acid | |
| US3143564A (en) | Method for producing 2-transvitamin a acid | |
| US3466335A (en) | Process for making the triaryl phosphonium salt of vitamin a alcohol | |
| US3275691A (en) | Dodecahydrophenanthrene derivatives | |
| US3903143A (en) | Stereoselective reduction of 9-keto prostanoic acids and esters | |
| US2709711A (en) | Synthesis of carotenoid polyenes | |
| US2534466A (en) | Octahydrophenanthrene-2-carboxylic acids and derivatives thereof | |
| US3284486A (en) | Process for the production of pyrethric acid | |
| US2835713A (en) | Chxch | |
| US3665039A (en) | Unsaturated aldehydes | |
| US2591110A (en) | Treatment of isomeric ester mixtures | |
| US3090791A (en) | Synthesis of griseofulvin and analogues, and intermediates therefor | |
| US4507290A (en) | Esters of 17 α-ethynyl 19-nor-testosterone and 17 α-ethynyl-18-homo-19-nor-testosterone and pharmaceutical compositions containing the same | |
| US4022804A (en) | Process for the production of bromo substituted tetrahydrofuran sulfones |